Market news

Rezdiffra's biggest growth opportunity may still be ahead.

Madrigal Pharmaceuticals (MDGL) drew attention after its second quarter 2026 earnings release, which highlighted Rezdiffra sales growth, stronger patient uptake, a smaller than expected quarterly loss, and revenue ahead of market estimates. See our latest analysis for Madrigal Pharmaceuticals. Despite solid interest in Rezdiffra and pipeline updates, Madrigal Pharmaceuticals’ share price has slipped recently, with the 30 day share price return down 8.16% and the year to date share price...

Madrigal Pharmaceuticals announced earlier on Friday that it has received three new U.S. patents for its lead drug, Rezdiffra.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is one of the 10 Best Under-the-Radar Stocks to Invest In. On June 11, BofA lowered its price target on Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to $542 from $550. It maintained a Neutral rating on the stock. The firm said Rezdiffra’s launch in MASH has impressed, but debate has shifted to whether […]